Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation

Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity. However, the majority of patients achieving remission with TKI still have molecular evidences of disease persistence. Various mech...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedel, Aurélie, Pasquet, Jean- Max, Lippert, Éric, Taillepierre, Miguel, Lagarde, Valérie, Dabernat, Sandrine, Dubus, Pierre, Charaf, Lucie, Beliveau, François, de Verneuil, Hubert, Richard, Emmanuel, Mahon, François-Xavier, Moreau-Gaudry, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751925/
https://www.ncbi.nlm.nih.gov/pubmed/24058405
http://dx.doi.org/10.1371/journal.pone.0071596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751925/
https://www.ncbi.nlm.nih.gov/pubmed/24058405
http://dx.doi.org/10.1371/journal.pone.0071596

Ejemplares similares